Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly shares grabbed attention Thursday, with the drugmaker reporting its experimental obesity and diabetes therapy, retatrutide, hit the primary endpoint in a late-stage trial—showing notable drops in both weight and blood sugar. The stock last changed hands at $918.05, off 1.3% early, after Tuesday’s nearly 6% tumble that followed a rare downgrade from HSBC.

19 March 2026

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health shares climbed 5.1% to $27.19 in premarket action as of 9:00 a.m. EDT on Thursday, following a 10.3% jump to $25.88 at Wednesday’s close. That put the telehealth company on track for its fourth consecutive advance.

12 March 2026

NASDAQ:HIMS·NYSE:LLY·NYSE:NVO·Stock Market

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said on Monday its experimental obesity drug ABBV-295 helped adults lose up to 9.79% of their body weight in 12 weeks in an early-stage study, giving the drugmaker its clearest sign yet that it may have a contender in a market led by Eli Lilly and Novo Nordisk. The company said no serious adverse events were reported.

10 March 2026

Health News·NYSE:ABBV·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Eli Lilly and Company wrapped up Tuesday’s session down roughly 1%, settling at $1,007.73. That followed a 3.23% drop the previous day.

4 March 2026

NASDAQ:VTYX·NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly and Company shares slipped 2.3% to $1,028.07 in Monday afternoon trading. Earlier in the session, the stock climbed as high as $1,056.84 but also dropped to $1,023.50 at its lowest. The drugmaker now holds a market value near $686 billion.

2 March 2026

HKG:1801·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock price rebounds above $1,050 — what traders are watching next

Eli Lilly and Co jumped 2.93% to finish at $1,051.99 on Friday, breaking a three-session slide. U.S. markets remain closed Saturday.

28 February 2026

NYSE:LLY·Stock Market

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Shares of Eli Lilly and Company jumped 2.93% to finish at $1,051.99 on Friday, breaking a three-session slump and pulling ahead of a broader market that dropped. The S&P 500 slipped 0.43%, while the Dow lost 1.05%, as traders grappled with stretched valuations and renewed jitters over the speed of artificial intelligence’s impact on market leaders and laggards.

28 February 2026

Biotechnology·NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly and Company ended Wednesday’s session off 1.28% at $1,028.83, with traders once again zeroing in on the obesity-drug story instead of the wider market action.

26 February 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly jumped roughly 4.9% to $1,058.23 late Monday, after Novo Nordisk revealed its next-gen obesity candidate, CagriSema, didn’t measure up to Lilly’s Zepbound in direct comparison. Novo's U.S. shares dropped sharply, sliding 16.4% to $39.63.

23 February 2026

Biotechnology·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

CSL share price slips as buyback tally grows; Lilly deal sets up next week

CSL Ltd slipped 0.6% Friday, ending the session at A$153.27. That pullback shaved off some of the gains from a two-day run-up earlier in the week.

20 February 2026

ASX:CSL·NYSE:LLY·Pharmaceutical Industry·Share Buybacks·Stock Market

Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly and Company turned in upbeat topline data from a pivotal trial of its cancer therapy Retevmo, teeing up a new challenge for the stock as U.S. markets get back to action Tuesday after the holiday.

16 February 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock price: $1.5 billion pill inventory puts April 10 FDA decision in spotlight

Eli Lilly and Company shares will be in the spotlight again when U.S. markets open Tuesday. The company revealed a $1.5 billion pre-launch inventory buildup for its oral weight-loss candidate, orforglipron. The stock last changed hands at $1,040.00, up roughly 0.2% from the previous finish. With markets closed Monday for Presidents Day, investors get one more day to process the update.

15 February 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock: LLY closes at $1,040 as $1.5 billion pill stockpile comes into focus

Eli Lilly finished Friday at $1,040, ticking up roughly 0.3%. Traders reacted to a fresh filing indicating the company’s been stockpiling its experimental weight-loss pill. Source: https://www.barrons.com/market-data/stocks/lly

14 February 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock price climbs as $1.5 billion pill stockpile sharpens focus on FDA April decision

Eli Lilly and Company shares edged up 0.6% to $1,044.62 by midday, having traded between $1,034.69 and $1,063.68 earlier.

13 February 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus

Eli Lilly and Company climbed almost 2% Thursday, pushing its rebound further as the company reported new regulatory progress for mirikizumab in China—a drug aimed at inflammatory bowel disease. By late morning, shares traded at $1,033.23, up 1.8%. The Health Care Select Sector SPDR Fund posted modest gains. Novo Nordisk’s U.S. shares, however, slipped.

12 February 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock price dips as $2.4 billion Orna deal and China pact grab attention

Eli Lilly and Company slipped 0.9% to $1,035.54 by 10:46 a.m. EST on Tuesday, giving back its early gains as the market reacted to fresh pipeline deals. Shares changed hands in a range from $1,032.21 to $1,054.31.

10 February 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock slides after-hours after $2.4 billion Orna deal — what to watch next for LLY

Eli Lilly and Co shares slipped roughly 1.3% to $1,044.67 in after-hours trading Monday, moving between $1,043 and $1,106.79.

9 February 2026

NYSE:LLY·Stock Market

Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk climbed 8.3% to 320 Danish crowns in Copenhagen by 10:50 a.m. local time, after Hims & Hers scrapped plans for a $49 weight-loss pill made with compounded semaglutide—the same compound found in Novo’s Wegovy and Ozempic.

9 February 2026

CSE:NOVOB.CO·NASDAQ:HIMS·NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly will take the spotlight Monday as Wall Street reopens, after Hims & Hers announced it’s pulling its compounded weight-loss pill in response to a U.S. Food and Drug Administration warning. Lilly's shares closed Friday at $1,058.18, rising 3.7%. “No one should be mass-compounding or selling knockoff GLP-1 products regardless of how they’re administered,” a Lilly spokesperson said.

8 February 2026

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Stock Market

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly and Company finished Friday’s session $37.34 higher, up 3.7% at $1,058.18 a share.

7 February 2026

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Previous 1 2 3 4 5 … 14 Next

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly stock price rebounds above $1,050 — what traders are watching next

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly stock price: $1.5 billion pill inventory puts April 10 FDA decision in spotlight

Eli Lilly stock: LLY closes at $1,040 as $1.5 billion pill stockpile comes into focus

Eli Lilly stock price climbs as $1.5 billion pill stockpile sharpens focus on FDA April decision

Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus

Eli Lilly stock price dips as $2.4 billion Orna deal and China pact grab attention

Eli Lilly stock slides after-hours after $2.4 billion Orna deal — what to watch next for LLY

Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

TechStock² Updates

Hyperliquid Strategies rises 5.5% as dilution cancels token discount

Ambev Stock Edges Up 0.3% as Volume Runs 72% Above Average

McDonald’s introduces SpongeBob and One Piece Happy Meals to encourage store traffic after U.S. sales edge up 0.8%

Broad ETFs Remain Stable as Oil Shock Cuts 374 Points From Dow

Snap Shares Gain 2.2% as 7.5% Cash-Flow Yield Eyes Buyback Evidence

NIO stock drops to 52-week low as options market signals 8.8% move on earnings

Nvidia Stock Up 1.5% as $20 Billion Buyback Represents 0.4% of Market Cap

Bank of America trades at 2.1x tangible book, could unlock $17 billion for buyback

UiPath climbs 2.9%, trading 63% above Q1 buyback price

Netflix Stock Slips 0.8% as Two Movies Capture Half of Top 10 Views

Investment Disclaimer